Eagle Asset Management Inc. Has $31.49 Million Stake in Kura Oncology Inc (NASDAQ:KURA)
Eagle Asset Management Inc. lifted its holdings in shares of Kura Oncology Inc (NASDAQ:KURA) by 1.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,075,747 shares of the company’s stock after buying an additional 31,878 shares during the quarter. Eagle Asset Management Inc.’s holdings in Kura Oncology were worth $31,489,000 at the end of the most recent quarter.
Several other large investors have also modified their holdings of the company. BlackRock Inc. grew its position in shares of Kura Oncology by 2.6% during the 2nd quarter. BlackRock Inc. now owns 2,407,038 shares of the company’s stock worth $47,396,000 after buying an additional 61,255 shares during the period. Vanguard Group Inc. grew its position in shares of Kura Oncology by 23.0% during the 2nd quarter. Vanguard Group Inc. now owns 2,012,548 shares of the company’s stock worth $39,628,000 after buying an additional 376,172 shares during the period. Victory Capital Management Inc. grew its position in shares of Kura Oncology by 12.0% during the 2nd quarter. Victory Capital Management Inc. now owns 1,967,270 shares of the company’s stock worth $38,736,000 after buying an additional 210,900 shares during the period. Brown Advisory Inc. acquired a new stake in shares of Kura Oncology during the 2nd quarter worth approximately $11,799,000. Finally, Northern Trust Corp grew its position in shares of Kura Oncology by 1.9% during the 2nd quarter. Northern Trust Corp now owns 385,478 shares of the company’s stock worth $7,591,000 after buying an additional 7,249 shares during the period. Institutional investors own 84.97% of the company’s stock.
KURA has been the subject of several analyst reports. Cowen reiterated a “buy” rating on shares of Kura Oncology in a research report on Wednesday. Deutsche Bank started coverage on shares of Kura Oncology in a research note on Thursday, July 18th. They set a “buy” rating and a $28.00 price objective on the stock. HC Wainwright reissued a “buy” rating and set a $29.00 price objective on shares of Kura Oncology in a research note on Friday, August 2nd. Wedbush reissued a “positive” rating on shares of Kura Oncology in a research note on Wednesday, September 4th. Finally, JMP Securities reissued a “market outperform” rating and set a $22.00 price objective on shares of Kura Oncology in a research note on Thursday, September 5th. One research analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $26.11.
Kura Oncology (NASDAQ:KURA) last issued its earnings results on Tuesday, November 5th. The company reported ($0.36) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.39) by $0.03. As a group, equities research analysts anticipate that Kura Oncology Inc will post -1.61 EPS for the current fiscal year.
Kura Oncology Profile
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Recommended Story: Why is cost of goods sold important?
Want to see what other hedge funds are holding KURA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kura Oncology Inc (NASDAQ:KURA).
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.